

## Anti-D immunoglobulin

## Section

Human immunoglobulins  
 Parenteral > General injections > IV: 250 µg in single-dose vial  
 Parenteral > General injections > IM: 250 µg in single-dose vial

## Indications

Rh incompatibility reaction

Maternal care for red cell antibodies

## Anti-rabies immunoglobulin

## Section

Human immunoglobulins  
 Parenteral > General injections > IM: 150 IU per mL in vial  
 Parenteral > Locoregional injections > Other: 150 IU per mL in vial

## Indications

Rabies

## Anti-tetanus immunoglobulin

## Section

Human immunoglobulins  
 Parenteral > General injections > IM: 500 IU in vial

## Indications

Tetanus

## C1 esterase inhibitor

## Section

Plasma-derived medicines  
 Parenteral > General injections > IV: 500 IU in vial powder for injection

## Indications

Hereditary angioedema

## Coagulation factor IX complex

## Section

Coagulation factors

## Indications

Therapeutic equivalent to coagulation factor IX, plasma-derived for

Coagulation defects, purpura or other haemorrhagic or related conditions

Therapeutic equivalent to coagulation factor IX, plasma-derived for

Haemophilia B

## Coagulation factor IX, plasma-derived

## Section

Coagulation factors  
 Parenteral > General injections > IV: 500 IU in vial powder for injection;  
 1000 IU in vial powder for injection

## Indications

Coagulation defects, purpura or other haemorrhagic or related conditions

Haemophilia B

## Coagulation factor IX, recombinant

### Section

#### Coagulation factors

Parenteral > General injections > IV: 250 IU per mL in vial lyophilized powder for solution for injection; 500 IU in vial lyophilized powder for solution for injection; 1000 IU in vial lyophilized powder for solution for injection; 1500 IU in vial lyophilized powder for solution for injection; 2000 IU in vial lyophilized powder for solution for injection; 3000 IU in vial lyophilized powder for solution for injection; 4000 IU in vial lyophilized powder for solution for injection

### Indications

Haemophilia B

## Coagulation factor VIII, plasma-derived

### Section

#### Coagulation factors

Parenteral > General injections > IV: 250 IU in vial powder for injection; 500 IU in vial powder for injection; 1000 IU in vial powder for injection

### Indications

Haemophilia A

## Coagulation factor VIII, recombinant

### Section

#### Coagulation factors

Parenteral > General injections > IV: 250 IU in vial lyophilized powder for solution for injection; 500 IU in vial lyophilized powder for solution for injection; 1000 IU in vial lyophilized powder for solution for injection; 1500 IU in vial lyophilized powder for solution for injection; 2000 IU in vial lyophilized powder for solution for injection; 3000 IU in vial lyophilized powder for solution for injection; 4000 IU in vial lyophilized powder for solution for injection

### Indications

Haemophilia A

## Cryoprecipitate (not pathogen-reduced)

Section	Indications
Blood and blood components	<p>Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for</p> <p>Coagulation defects, purpura or other haemorrhagic or related conditions</p> <p>Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for</p> <p>Obstetric haemorrhage</p> <p>Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for</p> <p>Haemophilia A</p> <p>Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for</p> <p>Von Willebrand disease</p>

## Cryoprecipitate (pathogen-reduced)

Section	Indications
Blood and blood components Injection: frozen liquid in bag or lyophilized powder in vial containing: > 50 IU Factor VIII > 100 IU vWF > 140 mg clottable fibrinogen per unit	<p>Coagulation defects, purpura or other haemorrhagic or related conditions</p> <p>Obstetric haemorrhage</p> <p>Haemophilia A</p> <p>Von Willebrand disease</p>

## Dextran 40

Section	Indications
Plasma substitutes	Hypovolaemia

## Dextran 70

Section	Indications
Plasma substitutes Parenteral > General injections > IV: 6% injectable solution	Hypovolaemia

## Fresh-frozen plasma

Section	Indications
Blood and blood components Parenteral > General injections > IV:	Blood transfusion without reported diagnosis

## Normal immunoglobulin

### Section

#### Human immunoglobulins

Parenteral > General injections > IV: 5% protein solution; 10% protein solution

Parenteral > General injections > IM: 16% protein solution

Parenteral > General injections > SC: 15% protein solution; 16% protein solution

### Indications

Primary immunodeficiencies

Langerhans cell histiocytosis

Mucocutaneous lymph node syndrome

## Platelets

### Section

#### Blood and blood components

Parenteral > General injections > IV:

### Indications

Blood transfusion without reported diagnosis

## Polygeline

### Section

#### Plasma substitutes

Parenteral > General injections > IV: 3.5% injectable solution

Parenteral > General injections > IV: 3.5% in solution

### Indications

Therapeutic equivalent to [dextran 70](#) for

Hypovolaemia

Hypovolaemia

## Red blood cells

### Section

#### Blood and blood components

Parenteral > General injections > IV:

### Indications

Blood transfusion without reported diagnosis

## Whole blood

### Section

#### Blood and blood components

Parenteral > General injections > IV:

### Indications

Blood transfusion without reported diagnosis